Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PVSRIPO |
Synonyms | |
Therapy Description |
PVSRIPO is an oncolytic virus comprising a recombinant poliovirus/rhinovirus chimera, which targets CD155 (Necl5)-expressing tumor cells, and potentially induces enhanced anti-tumor immune response and tumor cell cytotoxicity (PMID: 21984883, PMID: 24939611). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PVSRIPO | PVS-RIPO|NSC-719277|NSC719277 | PVSRIPO is an oncolytic virus comprising a recombinant poliovirus/rhinovirus chimera, which targets CD155 (Necl5)-expressing tumor cells, and potentially induces enhanced anti-tumor immune response and tumor cell cytotoxicity (PMID: 21984883, PMID: 24939611). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03712358 | Phase I | PVSRIPO | PVSRIPO for Patients With Unresectable Melanoma | Terminated | USA | 0 |
NCT04577807 | Phase II | PVSRIPO + unspecified PD-1 antibody PVSRIPO | PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma | Active, not recruiting | USA | 0 |
NCT03564782 | Phase I | PVSRIPO | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | Completed | USA | 0 |
NCT02986178 | Phase II | Lomustine + PVSRIPO PVSRIPO | PVSRIPO With/Without Lomustine | Active, not recruiting | USA | 0 |
NCT04599647 | Expanded access | PVSRIPO | EAP for the Treatment of Glioblastoma With PVSRIPO | No longer available | USA | 0 |